New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
13:13 EDTMDT
theflyonthewall.com: Medtronic: Earnings release technical preview, very high gap risk, bull pattern
BULLISH CASE: There is a bullish flag in progress on the daily chart. Upside potential is to the $44 area. The pattern would no longer be active on a breakdown below $40. On better than expected news/outlook the stock could trade to resistance at $40.56, $41.29, $41.99, $42.68, $43.38, $44.06, $44.80, $45.50, $46.20, $46.94. BEARISH CASE: On worse than expected news/outlook the stock could trade to the bottom of the bullish flag pattern at $38.92. On a bearish breakdown below the price pattern, the following support levels would become downside objectives: $38.56, $37.94, $37.25, $36.47, $35.88, $35.24, $34.65, $34, $33.28, $32.75. NOTE: Small short-base at 2 days to cover, with 1.1% of the float short. Traders are positioned for positive news. Reactions on a surprise, especially a negative one given the active bullish pattern and small short-base, have a high probability of being extreme in duration and price. Very high gap risk. :theflyonthewall.com



News For MDT From The Last 14 Days
Check below for free stories on MDT the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
08:39 EDTMDT
theflyonthewall.com: Edwards Lifesciences' new heart valve is less intrusive, IBD reports

Subscribe for More Information :theflyonthewall.com

January 28, 2010
12:05 EDTMDT
theflyonthewall.com: Medtronic announces two late breaking clinical trials accepted
Medtronic announced pivotal data for the Medtronic Arctic Front CryoAblation Catheter System will be presented as a late breaking clinical trial at the 59th Annual Scientific Session of the American College of Cardiology on Monday, March 15 at 8 a.m. ET. The STOP-AF clinical trial is evaluating the safety and efficacy of the Arctic Front CryoAblation Catheter System for paroxysmal atrial fibrillation patients. The system is approved for use in Europe, Australia and Hong Kong and is under investigational use in the United States. Additionally, data from the Medtronic-sponsored CONNECT clinical trial also will be presented as a late breaker on Monday, March 15. The trial is assessing how the use of the Medtronic CareLink Network to remotely monitor patients with Medtronic cardiac resynchronization therapy-defibrillators and implantable cardioverter-defibrillators equipped with Conexus Wireless Telemetry might effectively enable better patient care and reduce unnecessary healthcare costs. :theflyonthewall.com